DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for panuveitis — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePanuveitis maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for panuveitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 3 group C member 1 (NR3C1) — NR3C1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7KW7 · 3.57 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
A 43-year-old woman developed panuveitis with decreased vision three days after her second dose of Pfizer-BioNTech mRNA vaccine; the choroid was significantly thickened and there was anterior chamber and vitreous inflammation. She was also found to have an asymptomatic COVID-19 infection at the time. Oral and topical corticosteroids improved the panuveitis, but a mild recurrence occurred when these drugs were tapered. A 72-year-old woman developed bilateral panuveitis mimicking Vogt-Koyanagi-Harada disease three days after the first dose of the ChAdOx1 nCoV-19 vaccine, with headache, neck stiffness, and tinnitus. Systemic steroid therapy dramatically alleviated the panuveitis and meningeal signs, with no recurrence noted three months after stopping steroids. A 37-year-old man developed acute posterior multifocal placoid pigment epitheliopathy-like panuveitis two weeks after JYNNEOS mpox vaccination; symptoms and signs improved with topical and systemic corticosteroids with no recurrence over nine months off treatment.
A 46-year-old woman had blurred vision in both eyes eight days after COVID-19 symptoms began, with anterior chamber cells, mutton fat keratic precipitates, posterior synechiae, iris nodules, vitritis, and multiple superficial retinal infiltrates with retinal periphlebitis. Fluorescein angiography showed peripheral vascular leakage. The authors concluded that COVID-19 infection can cause granulomatous panuveitis via autoimmune mechanisms.
A retrospective review of 14 patients with sympathetic ophthalmia (mean age 48.5 years, mean follow-up 55.1 months) found that 71% had a history of ocular trauma and 29% had a history of ocular surgery. Time to symptom onset in the sympathizing eye ranged from 15 days to 60 years. The most common posterior segment findings were optic disc edema (36%) and exudative retinal detachment (36%). Mean choroidal thickness on enhanced depth imaging OCT was 716.5 μm in the acute period and decreased to 296 μm after treatment. Treatment included high-dose systemic corticosteroid (57%), azathioprine (50%), azathioprine and cyclosporine-A combination (50%), and tumour necrosis factor-alpha inhibitors (21%). Recurrence occurred in 29% of patients. At last follow-up, best corrected visual acuity was better than 20/50 in 79% of sympathizing eyes. Remission was achieved in 93% of patients, but one patient lost vision due to acute retinal necrosis.
A 69-year-old man presented with nonarteritic anterior ischemic optic neuropathy in the left eye, then one week later developed bilateral panuveitis with anterior chamber cells, vitreous cells, vasculitis, and exudates. No other autoimmune or infectious cause was found. Treatment with topical betamethasone alone led to improvement of optic disc edema and disappearance of retinal exudates in three months; best corrected visual acuity improved after cataract surgery.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Ocular Immunology and Inflammation · 2021 · 96 citations
Panuveitis following Vaccination for COVID-19
AbstractBackground: COVID-19 vaccination has been accompanied by reports of inflammatory events. This report details a case of panuveitis following vaccination for COVID-19 Case.Description: A 43 year old female developed panuveitis with decreased vision three days after her second dose of Pfizer-Biontech mRNA vaccine. The choroid was significantly thickened and there was anterior chamber and vitreous inflammation. Shortly after onset of ocular symptoms she was also found have an asymptomatic COVID-19 infection. Treatment with oral and topical corticosteroids resulted in improvement in the panuveitis, with a mild recurrence after the initial attempt to taper these drugs.Conclusion: This report demonstrates a likely occurrence of vaccine-related panuveitis secondary to the Pfizer-Biotech mRNA vaccine for COVID-19.
Ocular Immunology and Inflammation · 2022 · 15 citations
Bilateral Panuveitis Mimicking Vogt-Koyanagi-Harada Disease following the First Dose of ChAdOx1 nCoV-19 Vaccine
AbstractMETHOD: We report a case of bilateral panuveitis and its resolution based on multimodal retinal images after she was administered the first dose of a viral vector-based vaccine against SARS-CoV-2. CASE REPORT: A 72-year-old woman complained of bilateral blurred vision with headache, neck stiffness, and tinnitus 3 days after receiving the first dose of the ChAdOx1 nCoV-19 vaccine. Initial examination revealed anterior chamber reactions, left optic disc hyperemia, and bilateral chorioretinal folds with choroidal thickening. Fluorescein and indocyanine green angiography revealed bilateral choroiditis and papillitis. Systemic steroid therapy dramatically alleviated panuveitis and meningeal signs. No recurrence was noted until 3 months after discontinuation of steroids. CONCLUSIONS: Bilateral panuveitis mimicking Vogt-Koyanagi-Harada disease can develop shortly after the first dose of the ChAdOx1 nCoV-19 vaccine. Ophthalmologists should consider bilateral panuveitis as a presumed post-vaccination adverse event. Systemic steroid therapy may be effective for the nCoV-19 vaccine-associated panuveitis.
British Journal of Ophthalmology · 1993 · 12 citations · open access
Panuveitis and multifocal retinitis in a patient with leucocytoclastic vasculitis.
AbstractTo our knowledge, bilateral panuveitis and multifocal retinitis/vasculitis have not been described previously in association with leucocytoclastic vasculitis. We describe a patient with bilateral panuveitis associated with multifocal retinitis/vasculitis who also had multiple purpuric, palpable skin lesions. Biopsies of the skin lesions were diagnostic of leucocytoclastic vasculitis. An extensive examination for systemic disease was otherwise negative. Prompt treatment with systemic corticosteroids resulted in dramatic improvement ofboth the ocular and the skin lesions.
Ocular Immunology and Inflammation · 2022 · 5 citations
Bilateral Granulomatous Panuveitis in A Patient with COVID-19
AbstractPURPOSE: To present a case of panuveitis with granulomatous intraocular inflammation and vasculitis related to coronavirus disease 2019 (COVID-19). CASE REPORT: A 46-year-old female patient had blurred vision in both eyes during 8 days after COVID-19 symptoms. Anterior segment examination revealed anterior chamber cells in the both eyes, mutton fat keratic precipitates and posterior synechiae in the left eye. Small peripheral iris nodules and mild vitritis were accompanying in both eyes. Fundus examination revealed multiple superficial retinal infiltrate lesions in the peripheral retina with retinal periphlebitis in both eyes. Spectral domain optical coherence tomography showed hyperreflective superficial retinal infiltrates. Fluorescein angiography (FA) and indocyanine green angiography demonstrated hypofluorescent foci due to blockade of retinal infiltrates. Peripheral vascular leakage was detected on FA in both eyes. CONCLUSION: This case showed that COVID-19 infection can cause granulomatous panuveitis. Autoimmune mechanisms related to COVID-19 may lead to ocular inflammation.
Turkish Journal of Ophthalmology · 2023 · 2 citations · open access
Sympathetic Ophthalmia: Demographic Characteristics, Clinical Findings, and Treatment Results
AbstractObjectives: To evaluate the demographic characteristics, clinical findings, and treatment approach of patients with sympathetic ophthalmia (SO). Materials and Methods: The records of 14 patients with SO between 2000 and 2020 were retrospectively reviewed. The patients' Snellen best corrected visual acuity (BCVA), detailed ophthalmological examination, optical coherence tomography (OCT), enhanced depth imaging-OCT (EDI-OCT), fundus fluorescein angiography findings, and treatment approaches were recorded. Results: The study included the 14 sympathizing eyes of 14 patients with SO (7 female, 7 male). The mean age was 48.5±15.4 years (range: 28-75), and the mean follow-up duration was 55.1±48.7 months (range: 6-204). Ten patients (71%) had a history of ocular trauma and 4 (29%) had a history of ocular surgery. The time to symptom onset in the sympathizing eye after trauma or ocular surgery ranged from 15 days to 60 years. The most common posterior segment findings were optic disc edema (36%) and exudative retinal detachment (36%). In the acute period, the mean choroidal thickness value on EDI-OCT was 716.5±63.6 μm (range: 635-772) and decreased to 296±81.6 μm (range: 240-415) after treatment. Treatment with high-dose systemic corticosteroid was given to 8 patients (57%), azathioprine (AZA) to 7 (50%), AZA and cyclosporine-A combination to 7 (50%), and tumor necrosis factor-alpha inhibitors to 3 patients (21%). Recurrence was observed in 4 patients (29%) during follow-up. At last follow-up, BCVA values were better than 20/50 in 11 (79%) of the sympathizing eyes. Remission was achieved in 13 patients (93%), but 1 patient (7%) lost her vision due to acute retinal necrosis. Conclusion: SO is a bilateral inflammatory disease that presents with granulomatous panuveitis after ocular trauma or surgery. Favorable functional and anatomical results can be obtained with early diagnosis and initiation of appropriate treatment.
Ocular Immunology and Inflammation · 2025 · 2 citations
Acute Posterior Multifocal Placoid Pigment Epitheliopathy-Like Panuveitis Following Mpox Vaccination
AbstractPURPOSE: To report a case of APMPPE-like panuveitis following mpox vaccination. METHODS: Case report. RESULTS: A 37-year-old Chinese man presented with bilateral anterior and intermediate uveitis, retinal vasculitis and unilateral acute posterior multifocal placoid pigment epitheliopathy (APMPPE) 2 weeks following JYNNEOS mpox vaccination. Investigations excluded infectious and systemic inflammatory causes. Multi-modal imaging revealed features consistent with APMPPE in the left eye. His symptoms and clinical signs improved with topical and systemic corticosteroid therapy with no recurrence off treatment over a 9-month follow-up. CONCLUSION: Clinicians should be aware of the possibility of APMPPE-like panuveitis as a rare ocular complication following the mpox vaccine.
Clinical ophthalmology · 2013 · 0 citations · open access
A case of anterior ischemic optic neuropathy associated with uveitis
AbstractINTRODUCTION: Here, we describe a patient who presented with anterior ischemic optic neuropathy (AION) and subsequently developed uveitis. CASE: A 69-year-old man was referred to our hospital and initially presented with best-corrected visual acuities (BCVA) of 20/40 (right eye) and 20/1000 (left eye) and relative afferent pupillary defect. Slit-lamp examination revealed no signs of ocular inflammation in either eye. Fundus examination revealed left-eye swelling and a pale superior optic disc, and Goldmann perimetry revealed left-eye inferior hemianopia. The patient was diagnosed with nonarteritic AION in the left eye. One week later, the patient returned to the hospital because of vision loss. The BCVA of the left eye was so poor that the patient could only count fingers. Slit-lamp examination revealed 1+ cells in the anterior chamber and the anterior vitreous in both eyes. Funduscopic examination revealed vasculitis and exudates in both eyes. The patient was diagnosed with bilateral panuveitis, and treatment with topical betamethasone was started. No other physical findings resulting from other autoimmune or infectious diseases were found. No additional treatments were administered, and optic disc edema in the left eye improved, and the retinal exudates disappeared in 3 months. The patient's BCVA improved after cataract surgery was performed. CONCLUSION: Panuveitis most likely manifests after the development of AION.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
